Health Care
CSL Ltd (CSL)
CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.
Market Cap
A$65.3B
Shares on Issue
0.48B
Price Chart
AI Analysis
CSL's plasma network provides scale advantages, supporting margin recovery as collection volumes normalize. Pipeline momentum in immunology and hematology broadens the long-term growth profile.
The vaccine segment adds diversification, with steady demand from global immunization programs. Execution on R&D and manufacturing expansion will remain in focus for investors.
Bull Case
- • Plasma volume recovery supports earnings growth.
- • Deep R&D pipeline drives new product launches.
- • Global manufacturing footprint enhances resilience.
Bear Case
- • Competition in plasma therapies could pressure pricing.
- • Regulatory delays may slow product approvals.
- • High R&D spend can weigh on near-term margins.
Market Sentiment
Based on 123 social posts
Recent mentions
CBA jumps 7% on earnings
Australian shares expected to rise
ASX futures update
Recent Announcements
Update - Notification of buy-back - CSL
Update - Notification of buy-back - CSL
Notification regarding unquoted securities - CSL
Update - Notification of buy-back - CSL
Update - Notification of buy-back - CSL
FAQs
What does CSL produce?
CSL makes plasma-derived therapies, vaccines, and specialty biologic medicines.
Where does CSL operate?
CSL operates globally with major facilities in Australia, the US, and Europe.
What drives CSL earnings?
Plasma collection volumes, product pricing, and pipeline execution are key drivers.
Key Metrics
Related Stocks
Health Care
PNVPolynovo Ltd
A$0.91
-24.8% 1Y
Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.
Health Care
1ADAdalta Limited
A$0.00
-20.6% 1Y
Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.
Health Care
1AIAlgorae Pharmaceuticals Limited
A$0.01
150.0% 1Y
Algorae Pharmaceuticals is an Australian drug discovery company utilizing its proprietary artificial intelligence platform, AlgoraeOS, to identify and develop novel therapeutic treatments. The company focuses on creating drug candidates for conditions with unmet medical needs, including dementia, cardiovascular disease, and Meniere's disease. Its business model is centered on leveraging AI to accelerate the traditionally lengthy and costly process of pharmaceutical research and development.